Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Director Michael G. Grey Sells 14,216 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Director Michael G. Grey sold 14,216 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $32.00, for a total value of $454,912.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Mirum Pharmaceuticals Stock Up 8.0 %

Shares of NASDAQ MIRM opened at $32.36 on Friday. Mirum Pharmaceuticals, Inc. has a 52-week low of $17.32 and a 52-week high of $32.53. The firm has a fifty day moving average of $26.45 and a 200-day moving average of $25.95. The company has a debt-to-equity ratio of 3.89, a current ratio of 6.59 and a quick ratio of 6.44.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Thursday, August 3rd. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.11). The business had revenue of $37.50 million for the quarter, compared to analyst estimates of $30.00 million. Mirum Pharmaceuticals had a negative net margin of 152.27% and a negative return on equity of 103.59%. On average, sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -2.41 EPS for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in MIRM. Silverarc Capital Management LLC lifted its holdings in Mirum Pharmaceuticals by 0.4% in the 2nd quarter. Silverarc Capital Management LLC now owns 106,375 shares of the company’s stock worth $2,752,000 after buying an additional 436 shares in the last quarter. Metropolitan Life Insurance Co NY lifted its holdings in Mirum Pharmaceuticals by 49.7% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 1,464 shares of the company’s stock worth $38,000 after buying an additional 486 shares in the last quarter. Royal Bank of Canada lifted its holdings in Mirum Pharmaceuticals by 40.1% in the 2nd quarter. Royal Bank of Canada now owns 1,851 shares of the company’s stock worth $48,000 after buying an additional 530 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Mirum Pharmaceuticals by 4.9% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,037 shares of the company’s stock worth $358,000 after buying an additional 654 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Mirum Pharmaceuticals by 5.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 15,500 shares of the company’s stock worth $342,000 after buying an additional 804 shares in the last quarter.

Analysts Set New Price Targets

MIRM has been the subject of several recent analyst reports. Raymond James lifted their target price on shares of Mirum Pharmaceuticals from $79.00 to $84.00 and gave the stock a “strong-buy” rating in a research note on Monday, August 21st. HC Wainwright reissued a “buy” rating and set a $63.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.